EDGAR·FLOW

LISATA THERAPEUTICS, INC. — Form 8-K

Filed November 19, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 28/100
What the filing says
Lisata Therapeutics approved and implemented a 1-for-15 reverse stock split, reducing outstanding shares from approximately 10.8 million to approximately 0.7 million shares, effective November 23, 2026. The split does not change stockholder ownership percentages (except minor fractional adjustments) or authorized shares, and fractional shares will be paid in cash at the November 19, 2026 closing price. All convertible securities and options are adjusted proportionally.
Why this rating

Reverse split is administrative/cosmetic capital structure change. No material business impact, dilution, or strategic shift. Routine for small-cap companies facing exchange listing pressure.

View original filing on SEC.gov ↗ LSTA · stock on Yahoo Finance ↗

See more from November 19, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.